Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, multiple sclerosis) have a high prevalence, affecting 9 million people in Europe, and are the cause of major disability impacting patients as well as their families.
Various factors such as the heterogeneity of these diseases, lack of biomarkers for their early diagnosis, lack of preclinical models and the lack of truly effective therapies, induce that the management of these diseases becomes more and more problematic. Therefore, in order to face this challenge and initiate changes, DHUNE was created.
The mission of DHUNE is to create and tighten the links between care, education, preclinical and clinical research, as well as valorisation.
Professor Olivier Blin, coordinator of the DHUNE program and director of the clinical unit of Pharmacology and Pharmacovigilance at AP-HM explains: "The research in France will receive a new face. Pharmacy, biology, psychiatry, gerontology, neuroscience, social sciences ... since October 2015, and for a period of 5 years, 34 teams of researchers across all sectors, including industries, networks of care as well as patient associations, engage in this considerable research project on neurodegenerative diseases. "